Availability, prices and affordability of essential medicines in Haiti

por Chahal, Harinder Singh, St. Fort, Nazaire, Bero, Lisa
Publicado 2013

Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants

por Chahal, Harinder Singh, Mukherjee, Sanjana, Sigelman, Daniel W., Temple, Robert
Publicado 2021

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021

por Monge, Andrea N., Sigelman, Daniel W., Temple, Robert J., Chahal, Harinder Singh
Publicado 2022

Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study

por Lurie, Peter, Chahal, Harinder S, Sigelman, Daniel W, Stacy, Sylvie, Sclar, Joshua, Ddamulira, Barbara
Publicado 2015

The US Food and Drug Administration's tentative approval process and the global fight against HIV

por Chahal, Harinder Singh, Murray, Jeffrey S, Shimer, Martin, Capella, Peter, Presto, Ryan, Valdez, Mary Lou, Lurie, Peter G
Publicado 2017

Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment

por Chahal, Harinder Singh, Capella, Peter, Presto, Ryan, Murray, Jeffrey S, Shimer, Martin, Valdez, Mary Lou, Lurie, Peter G
Publicado 2018

An Evaluation of US Food and Drug Administration’s Program to Register HIV Drugs for Use in Resource-Constrained Settings

por Chahal, Harinder Singh, Koukounas, Kalli, Capella, Peter, Presto, Ryan, Murray, Jeffrey S., Shimer, Martin, Riley, Karen, Valdez, Mary Lou
Publicado 2019